Nov. 27 at 2:35 AM
$MAIA Biotech investing isn't for the weak. Lots of MAIA naysayers are just inexperienced clowns that don't know how to read clinical data, don't understand the industry, and don't understand the business case for ateganosine. They probably haven't read a single 10K or 10Q in their life.
With M&A and deal-making activity accelerating, and patent cliffs coming to crush biopharma revenues over the next 5 years, MAIA is PERFECTLY positioned for a massive rocket to
$10+. It could come from investor sentiment improving, a licensing agreement, or an outright purchase of the entire company. Regardless of how it comes, the point is that it will come. MAIA's clinical data is backed by Regeneron, Roche, BeOne, the FDA, and even the NIH. The value is in the data, and biopharma companies are having bidding wars for companies with derisked assets.
📈💰🤑💰📈
